ABSTRACT
KEY WORDS: alemtuzumab, chronic lymphocytic leukemia (CLL), minimal residual disease (MRD), monoclonal antibodies (mAb), rituximab
Identication of cancer-specic antigens is changing the therapeutic algorithm of chronic lymphocytic leukemia (CLL). Monoclonal antibodies (mAb), as monotherapy or in combination with conventional chemotherapy, are becoming integral therapies for CLL. Alemtuzumab is a humanized anti-CD52 IgG1 mAb that is approved by the U.S.
